GH Research (NASDAQ:GHRS) Stock Bumped Up to Hold by Wall Street Zen

Wall Street Zen upgraded shares of GH Research (NASDAQ:GHRS) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Other research analysts also recently issued research reports about the stock. Stifel Nicolaus set a $38.00 price objective on shares of GH Research in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a research note on Thursday, October 15th. Cantor Fitzgerald raised their target price on GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Wells Fargo & Company initiated coverage on GH Research in a research note on Monday, July 27th. They issued an “overweight” rating and a $44.00 price target for the company. Finally, Guggenheim upped their price target on GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.36.

GH Research Stock Performance

NASDAQ GHRS traded up $0.61 on Friday, reaching $19.10. 560,158 shares of the company’s stock traded hands, compared to its average volume of 322,223. GH Research has a fifty-two week low of $12.04 and a fifty-two week high of $31.44. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -19.10 and a beta of 1.31. The stock has a 50 day moving average price of $22.30 and a 200-day moving average price of $21.64.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.13. As a group, equities research analysts anticipate that GH Research will post -1.20 EPS for the current fiscal year.

Institutional Investors Weigh In On GH Research

A number of hedge funds have recently modified their holdings of GHRS. Troluce Capital Advisors LLC boosted its holdings in shares of GH Research by 165.4% during the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after purchasing an additional 617,260 shares during the last quarter. Braidwell LP purchased a new stake in shares of GH Research in the second quarter valued at approximately $5,571,000. Marshall Wace LLP increased its holdings in shares of GH Research by 46.3% in the third quarter. Marshall Wace LLP now owns 68,298 shares of the company’s stock valued at $1,604,000 after purchasing an additional 21,601 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of GH Research in the first quarter valued at approximately $290,000. Finally, Squarepoint Ops LLC purchased a new position in GH Research during the second quarter worth approximately $495,000. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.